Compounded vs FDA-Approved Bioidentical Hormones
Placeholder lead: compounded products skip standard FDA approval review.
- None: FDA review (Placeholder: compounded skip review)
- Many: Approved options (Placeholder: FDA-approved alternatives exist)
- Rare: Batch testing (Placeholder: compounding pharmacies vary)
- Common: Prescriber use (Placeholder: widely prescribed off-label)
Regulatory pathway differences
Placeholder: compounded products are pharmacy-made, not FDA-batch-approved.
Lack of Standardized Quality Testing
Placeholder lead: many compounding pharmacies lack routine potency testing.
- Up to 25%: Potency variance (Placeholder: found in some studies)
- Inconsistent: Sterility testing (Placeholder: not always required)
- Optional: Third-party audits (Placeholder: voluntary accreditation)
- Nonzero: Contamination risk (Placeholder: past outbreak examples)
Testing gaps across pharmacies
Placeholder: testing rigor differs widely between compounding facilities.
Dose Consistency Variability Concerns
Placeholder lead: compounded batches can differ from labeled dose.
- Variable: Batch-to-batch (Placeholder: dosing can drift)
- ±10–30%: Assay deviation (Placeholder: reported ranges)
- ±5%: Approved variance (Placeholder: FDA manufacturing limit)
- Under/over dose: Patient impact (Placeholder: possible outcomes)
Why consistency matters
Placeholder: hormone therapy requires precise, reproducible dosing.
Marketing Claims vs Evidence Gap
Placeholder lead: bioidentical marketing often outpaces clinical trial data.
- Limited: RCT support (Placeholder: few large trials)
- Unregulated: "Natural" claims (Placeholder: marketing term, not clinical)
- Incomplete: Safety data (Placeholder: long-term data sparse)
- Cautionary: Society guidance (Placeholder: major bodies urge caution)
Claims vs clinical trials
Placeholder: many benefit claims lack robust trial support.
When Compounding May Be Appropriate
Placeholder lead: compounding can help with allergies or unavailable dose forms.
- Valid use: Allergy cases (Placeholder: excipient allergy example)
- Valid use: Unavailable strength (Placeholder: dose not commercially made)
- Not advised: Routine substitute (Placeholder: avoid as default choice)
- Required: Physician oversight (Placeholder: monitored prescribing needed)
Narrow appropriate scenarios
Placeholder: compounding fits niche cases, not routine therapy.
Placeholder highlight: always discuss compounding risks with a prescriber.